Bocaparvovirus small noncoding rna and uses thereof

Abstract

Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complement of the nucleotide sequence, and methods of using the vectors, are provided.

1 . (canceled) 
     
     
         2 . A vector comprising:
 a nucleotide sequence having SEQ ID NO: 1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus (BoV) replication, wherein the nucleotide sequence does not encode BoV NS1;   a vector comprising a nucleic acid segment that has a sequence that is a complement to a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that inhibits expression of SEQ ID NO:1; or   a vector having a recombinant BoV genome comprising a LEH, a 3′ UTR and a REH, wherein the 3′ UTR includes a nucleotide sequence having at least 85% identity to SEQ ID NO: 1, or a portion thereof that is capable of regulating BoV replication, wherein the REH includes a 46 nucleotide sequence comprising OriR having a TRS and a NS1 nicking or binding site, wherein the genome encodes BoV NP1, NS4 or NS2, and optionally VP1, VP2 and/or VP3, or any combination thereof, but not NS1.   
     
     
         3 . The vector of  claim 2 , which comprises a promoter operably linked to the nucleotide sequence having at least 85% identity to SEQ ID NO: 1 or a promoter which is optionally a PolIII promoter such as a U6 or HI promoter, or an intron operably linked to the nucleic acid segment. 
     
     
         4 . The vector of  claim 2 , which further encodes one or more of BoV NS3/4, NS4, NS2, NP1, VP1, VP2, and VP3 or which further encodes one or more of BoV NP1, VP1, VP2, and VP3 or encodes BoV NP1 and NS2 or NS4. 
     
     
         5 . The vector of  claim 2 , which is in a viral vector or plasmid. 
     
     
         6 . The vector of  claim 5 , which is an adenovirus vector, an adeno-associated virus vector, a chimeric rAAV/BoV vector, or a lentivirus vector. 
     
     
         7 . The vector of  claim 2 , which is in a liposome or which is part of a microparticle or nanoparticle. 
     
     
         8 . The vector of  claim 2 , wherein the OriR includes nucleotides 5357 to 5402 or nucleotides 5357 to 5430 of SEQ ID NO: 25 or a sequence with at least 90% nucleic acid sequence identity thereto. 
     
     
         9 . The vector of  claim 2 , wherein the OriR includes (TGT) a -(TGT) b -(TGT) c -(TGT) d , where each of a, b, c or d independently is 0 or 1, wherein at least two of a, b, c, and d=1, and wherein if a, b, c and d=1, the T or G in the TGT for no more than two of a, b, c or d may be replaced with C, G, or any combination thereof. 
     
     
         10 . The vector of  claim 2 , wherein the nicking site includes CTA/TATCT. 
     
     
         11 . The vector of  claim 2 , wherein the vector comprises a heterologous promoter.